Background {#Sec1}
==========

Inherited ichthyosis (II) is a heterogeneous group of genetic diseases characterized by scaling that affects the entire skin, and is often associated with hyperkeratosis and skin inflammation \[[@CR1]\]. Other symptoms include heat intolerance, pruritus, pain, conductive deafness, and ocular complications, e.g., caused by ectropion. II is primarily a monogenic disease, with more than 40 gene mutations identified (to date) that cause a defective skin barrier \[[@CR2]\]. Its classification is based on its clinical presentation and is basically distinguished between non-syndromic (including common ichthyoses, autosomal recessive congenital ichthyosis, keratinopathic ichthyosis, and other forms) and syndromic ichthyoses \[[@CR2]\]. II usually has a strong impact on quality of life and requires lifelong treatment \[[@CR3], [@CR4]\].

As yet there is no curative therapy. Topical agents represent the first-line treatment. If they are not fully effective or if skin-care is very burdensome, oral retinoids may be considered. There are three types of oral retinoids available: acitretin, alitretinoin and isotretinoin. Etretinate is no longer available in most countries.

Acitretin is the main retinoid prescribed and the only one approved in Europe to treat II \[[@CR5]\]. The risk/benefit balance of acitretin is considered favorable, but teratogenesis in women wishing to become pregnant is the main concern, with contraindications to pregnancy for 3 years after acitretin-treatment is discontinued. Acitretin may also not be fully efficacious and can be associated with other adverse effects or, rarely, hypersensitivity \[[@CR6]\].

Alitretinoin (Toctino®) (9 cis-retinoic acid) is a recent oral retinoid that has more rapid clearance and, consequently, a shorter teratogenic risk (only 1 month after drug discontinuation). It is approved in Europe for severe chronic hand eczema that is unresponsive to potent topical corticosteroids \[[@CR7], [@CR8]\]. In this setting, the recommended dosage is 10 or 30 mg once daily, with dose adjustments based on efficacy and tolerability. There are only a few literature reports in II patients \[[@CR9]--[@CR11]\]. We report here on the effect and tolerability to alitretinoin in a series of patients with II.

Methods {#Sec2}
=======

This observational retrospective multicentric study was performed in three French centers that specialized in II (Toulouse, Paris, Nice). All patients with II and treated with alitretinoin (ongoing or previous treatment) between January 2014 and June 2017 were included. This study was approved by the statutory and ethics authorities according to new French regulations (Loi Jardé). Data were obtained from medical records and photographs.

The clinical parameters (erythema, scaling or hyperkeratosis, palmoplantar keratoderma, ectropion) were assessed using visual analog scales (VAS: 0-10) at two different time-points: before and after introducing alitretinoin (patients were assessed after at least 1 month receiving the maximum dosage). Prominent clinical sign was identified for each patient based on the physician's opinion and the patient's opinions/ impact on quality of life. The efficacy of alitretinoin was defined as high, moderate, or low according to if a decrease in the prominent clinical sign was ≥ 3, between 2 and 1, or \< 1, respectively. The patient was also asked to evaluate the global efficacy of alitretinoin (high, moderate, or low/absent), and any side-effects were recorded.

Results {#Sec3}
=======

A total of 13 patients were included in this study; their characteristics are described in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of the 13 cases inherited ichthyosis treated by alitretinoinPatientsGenderAge at start of studyMutated geneForm of IIAcitretin treatment before starting ALReasons for introducing ALMaximum dosage of AL (mg/day)AL duration\
(months)Side effects of ALTreatment change ~~for~~ due to side effectsCauses of AL withdrawalMonitoring1M24*ICTHYN*LIYesAC IE3036Moderate headacheRDSE\
IE at 10 mg/dayLipid, liver2F33*CYP4F22*LIYesDesire for pregnancy101------Lipid, liver, *β*-HCG3F32*ICTHYN*LIYesDesire for pregnancy3012Moderate headacheRDSE\
IE at 10 mg/dayLipid, liver, *β*-HCG4F34*ICTHYN*LIYesDesire for pregnancy3036------Lipid, liver, *β*-HCG5F36*ICTHYN*LIYesDesire for pregnancy3024------Lipid, liver, *β*-HCG6F28*SPINK5*NSNoDesire for pregnancy306Benign intracranial hypertensionSSELipid, liver, *β*-HCG7M12*ABCA12*CIEYesAC SE (mucous dryness)1018------Lipid, liver, *β*-HCG8M38Not identifiedCIEYesAC SE (myalgia)3012------Lipid, liver, *β*-HCG9F35*ABCA12*CIENoDesire for pregnancy3024Moderate headache----Lipid, liver, *β*-HCG10F30*POMP*KLICKYesDesire for pregnancy1016------Lipid, liver, *β*-HCG,TSH,T4 X-rays11F25*TGM1*LIYesDesire for pregnancy\
AC IE3015Myalgia----Lipid, liver, *β*-HCG,TSH,T4 X-rays12F23ongoingLIYesDesire for pregnancy\
AC IE202Severe headache\
Mucous oral dryness----Lipid, liver, *β*-HCG,TSH,T4,X-rays13F28*GJB3*EKYesDesire for pregnancy302Mucous oral dryness----Lipid, liver, *β*-HCG,TSH*AL* alitretinoin, *AC* acitretin, *CIE* congenital ichthyosiform erythroderma, *EK* erythrokeratoderma, *IE* insufficient efficacy, *KLICK* keratosis linearis ichthyosis congenital keratoderma, *LI* lamellar ichthyosis, *M* months, *NS* Netherton syndrome, *RD* reduced dosage, *S* stopped treatment, *SE* side-effects, *Y* years

There were three males and ten females (all of childbearing age); overall median age was 30 years \[range: 12-38\]. None had a significant previous medical history. Ten patients suffered from congenital ichthyosis, seven of them having lamellar ichthyosis (*Ichthyn: n* 4, *CYP4F22:* n 1, *TGM1: n* 1, ongoing analysis: n 1) and three cases of congenital ichthyosiform erythroderma (two patients who carried *ABCA12* mutations, and one who had no identified mutation). The remaining three patients had Netherton syndrome (one case due to *SPINK5* mutations), erythrokeratoderma (one case due to *GJB3* mutation), and KLICK (keratosis linearis with ichthyosis congenita and sclerosing keratoderma) syndrome (one case carrying *POMP* mutation). The prominent sign was scaling in five patients (five with lamellar ichthyosis with a VAS between 5 and 9) and erythema for the other eight patients (two with lamellar ichthyosis, one case of Netherton syndrome, three with congenital ichthyosiform erythroderma, one with KLICK syndrome, one with erythrokeratoderma; VAS was between 5 and 8) (Table [2](#Tab2){ref-type="table"}).Table 2Effects of alitretinoin on 13 patients with inherited ichthyosisPatientsForm of IIProminent signAlitretinoin' efficacy on the prominent signDosage of AL at the time of the final VAS evaluation (mg/day)Global efficacyVAS Scale (0-10)\
Before - during ALVAS erythema (0-10)\
Before - during ALVAS Palmoplantar keratoderma\
(0-10)\
Before - During ALVAS\
Ectropion\
(0-10)\
Before - During AL1LISLow10Low5-70-04-40-02LIEHigh10High5-35-12-20-03LISLow10Low5-70-04-40-04LISModerate30Moderate5-30-03-20-05LIEModerate30Moderate5-46-~~4~~1-10-06NSEHigh30High6-48-33-20-07CIEEModerate10Moderate4-37-54-40-08CIEEModerate30Moderate3-35-32-20-09CIEEModerate30Moderate5-47-59-84-410KLICKEModerate10Moderate4-36-45-40-011LISModerate30Moderate9-72-16-58-812LISModerate20Moderate9-72-26-58-713EKEModerate30Moderate7-76-46-50-0*E* erythema, *S* scales/hyperkeratosis, *VAS* visual analogical scale

When introducing alitretinoin, 11 patients had been prescribed acitretin, which was consequently stopped. The median dosage of acitretin had been 0.4 mg/kg/day \[range: 0.2-0.5\] and the median duration of treatment was 84 months \[range: 1-252\]. The main reason for introducing alitretinoin was a desire to become pregnant for all ten female patients, of which two had a very severe disease (VAS scale: 9/10). The replacement of acitretin with alitretinoin was also because of insufficient treatment efficacy. All three males had been prescribed acitretin but wanted to change treatment because of its side effects (mucous dryness and myalgia) or insufficient efficacy. No changes to skin care were made during treatment with alitretinoin (Table [2](#Tab2){ref-type="table"}). The starting dose of alitretinoin was 10 mg per day for all patients. For nine patients, this dose was increased after 1 month to 30 mg. For patient 12, dosage was only increased to 20 mg after 2 months because of headaches. The other three patients were maintained on 10 mg per day as the treatment was fully efficacious.

The reduction in scaling was not consistent between the five patients that had prominent scaling, with VAS either decreasing or increasing. All eight patients with prominent erythema had a reduction in VAS (median improvement of 2 points \[range: 2-5\]). Their scaling remained stable or slightly improved.

The assessment of other parameters (palmoplantar keratoderma or ectropion) did not reveal any significant improvement with treatment.

Alitretinoin global efficacy was considered low in two patients, moderate in nine and high in two patients. These latter two patients had lamellar ichthyosis caused by a *CYP4F22* mutation and Netherton syndrome, respectively (for these patients, the VAS erythema was reduced by 4 and 5 points, respectively).

Blood tests included assessment of liver-enzyme levels and a lipid profile (cholesterol, triglycerides) for all patients, and assessment of T4 and thyroid-stimulating hormone for six patients. The tests were performed for all patients at baseline, and then after 1 month and then at different time points (each month or every 3 months). *β*-HCG was assessed monthly in women of childbearing age. X-rays (spinal and pelvis) were performed on only three patients at baseline.

The reported side-effects were as follows: moderate to severe headaches (four patients, of which three were receiving 30 mg/day, required analgesics on demand; and one patient who presented spontaneous resolution of headaches after 8 weeks treatment with alitretinoin 10 mg/day, allowing drug dosage increase to 20 mg/day), oral mucous dryness (two patients receiving 10 or 30 mg/day), myalgia (one patient), benign intracranial hypertension presenting with headaches, blurred vision, and papilledema (an MRI of the brain was unremarkable), which completely resolved after withdrawal of alitretinoin (one patient). The benign intracranial hypertension was the only side effect that led to drug discontinuation. Alitretinoin was also discontinued in two patients that needed a decreased dose because of moderate headache and, consequently, they experienced inadequate treatment efficacy.

Discussion {#Sec4}
==========

We report here on the largest series of patients with II and treated using alitretinoin. We show that alitretinoin was effective at reducing erythema and was otherwise well-tolerated.

There are some limitations to our study. One was related to the rarity of II, and thus the small number of included patients. The second limitation is related to the retrospective design of the study, with different dosages and treatment durations. We were also not able to compare the effect on alitretinoin to baseline data as most patients were receiving acitretin at the time when alitretinoin therapy was started.

In the literature, the effect and tolerance to alitretinoin has only been reported for six patients: a case series of four patients \[[@CR11]\] and two case reports on KID (keratitis ichthyosis deafness) syndrome \[[@CR9], [@CR10]\].

The series by Gånemo et al., included four cases of II: one had epidermolytic ichthyosis (caused by a *KRT10* mutation) and three had lamellar ichthyosis (caused by a *TGM1* mutation). In contrast to our study, none of the cases had prominent erythema. All four patients had decreased scaling (no score provided) using high-dose alitretinoin (30-60 mg/day). However, this improvement was not better than previously observed with acitretin, except for the patient with epidermolytic ichthyosis. Dry lips were reported by all patients at the highest dose, and one experienced mild myalgia and another reported having headaches. Two patients had changed levels of thyroid hormone: one patient reverted to baseline values after alitretinoin was suspended, and the other showed signs of autoimmune hypothyroidism \[[@CR11]\].

In the other studies, two patients with KID syndrome had reduction~~s~~ in hyperkeratosis and erythema and no significant side-effects when using a dosage of 20 or 30 mg/day of alitretinoin \[[@CR9], [@CR10]\].

In a series of 16 cases of epidermolytic ichthyosis, the efficacy of different oral retinoids, including alitretinoin, was reported. Only three patients had an acceptable response to treatment, but the effects of alitretinoin were not assessed separately and the dosage of alitretinoin was not mentioned \[[@CR12]\].

All these data suggest that alitretinoin is not effective at reducing scaling or palmoplantar keratoderma, even at high doses. In contrast, alitretinoin seemed effective at reducing erythema (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). The best VAS improvement (from 8 to 2) was experienced by the patient affected by NS, a clinical form of ichthyosis which is particularly characterized by erythroderma. This efficacy on erythema seems to be fast since it was seen after only 1 or 2 months for patients 2,12,13.Fig. 1Patient 9 with congenital ichthyosiform erythroderma due to *ABCA12* mutation: comparison of the erythema on the face and dorsal aspects of the hands before alitretinoin (VAS 7) (**a**, **b**) and after 24 months on alitretinoin (dosage of 30 mg per day) (**c**, **d**)Fig. 2Patient 13 with erythrokeratoderma due to *GJB3* mutation: comparison of the erythema on the dorsal aspect of the hands, the external side of lower leg and ankle, the knees before alitretinoin (VAS 6) (**a**, **b**, **c**) and after 2 months on alitretinoin (dosage of 30 mg per day) (**c**, **d**, **e**)

The fact that alitretinoin improves erythema enhances the hypothesis of an anti-inflammatory effect. This is in accordance with efficacy of alitretinoin to reduce erythema in patients that have chronic hand eczema \[[@CR7]\] or KID syndrome \[[@CR9], [@CR10]\].

Alitretinoin thus seems to be suitable to treat II associated with prominent erythema. The dosage of 10 mg per day may be sufficient for some patients, whereas others may require higher doses (up to 30 mg). There are no published data on the effect of alitretinoin on ectropion. In our series, only three patients had ectropion and remained stable under alitretinoin.

It was intriguing to note that two sisters with similar phenotypes (patients 3 and 4) had different skin responses (improvement or worsening) using a similar dosage of alitretinoin, suggesting inter-individual variability in drug response. Some authors suggest that the response to retinoids should also be influenced by the causal gene: patients with epidermolytic ichthyosis caused by a *KRT10* mutation responding better than those with a *KRT1* mutation \[[@CR11], [@CR13]\].

The side-effects reported with alitretinoin do not seem to differ from those with acitretin, except for thyroid dysfunction (not reported in our series) and headache (more frequent with alitretinoin). These side-effects occasionally led to discontinuation of treatment. The most serious side-effect was seen in a patient with Netherton syndrome where treatment had to be interrupted despite excellent improvement in skin features.

Due to a paucity of data in the literature, the exact incidence of benign intracranial hypertension (pseudotumor cerebri) is unknown. Safety analysis of the pivotal studies and postmarketing adverse events since alitretinoin approval, only revealed eight cases of benign intracranial hypertension \[[@CR14]\]. This side-effect may be observed in patients taking other drugs (such as tetracycline), concomitantly \[[@CR15]\].

Conclusion {#Sec5}
==========

Alitretinoin may be suitable for those with II and prominent erythema, especially for women of childbearing age. A dosage of 10 mg per day may be sufficient in some cases. The risk/benefit balance of alitretinoin seems favorable, but monitoring is necessary, as is recommended for other similar diseases or for acitretin therapy \[[@CR7], [@CR9], [@CR11]\]. This prescription remains off-label and larger prospective controlled studies are needed to confirm these results.
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